Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation
- On February 21, 2023, Piper Sandler initiated coverage of Galera Therapeutics with a Overweight recommendation.
- 02/21/2023
|
Galera to Present at Piper Sandler Annual Healthcare Conference
- MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T.
- 11/22/2022
|
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
- MALVERN, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that tumor outcomes data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis (SOM) and final data from its Phase 2 AESOP trial of avasopasem for chemoradiotherapy-induced esophagitis will be highlighted in two presentations at the upcoming 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place October 23-26, 2022 in San Antonio, Texas. Additionally, poster presentations will highlight the Phase 2 EUSOM trial of avasopasem for SOM in Europe and the ongoing GRECO-1 trial of rucosopasem for non-small cell lung cancer.
- 09/26/2022
|
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
- MALVERN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 4:30 p.m. E.T.
- 09/06/2022
|
Galera Therapeutics' Rucosopasem Shows Early Anti-Cancer Activity, Pulmonary Function Preservation
- Galera Therapeutics Inc (NASDAQ: GRTX) announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC). Enrollment is ongoing in the randomized, double.
- 06/29/2022
|
Galera to Present at Jefferies Healthcare Conference
- MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. E.T.
- 06/02/2022
|
Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
- Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome.
- 03/23/2022
|
Galera to Present at H.C. Wainwright BioConnect Conference
- MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.
- 01/06/2022
|
Top Penny Stocks to Buy in 2022? Check These 3 Out Right Now
- Which penny stocks are you buying right now? The post Top Penny Stocks to Buy in 2022?
- 01/01/2022
|
Trending Penny Stocks to Buy Today? 3 For Your Watchlist
- Which penny stocks are you watching right now? The post Trending Penny Stocks to Buy Today?
- 12/21/2021
|
Galera Therapeutics Stock (GRTX): Why The Price Surged Today
- The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by 28.04% today. This is why it happened.
- 12/20/2021
|
Galera Therapeutics Shares Surge As Citi Bumps Up Price Target To $20
- Citi has raised the price target on Galera Therapeutics Inc (NASDAQ:GRTX) to $20 (suggesting 361% upside) from $11 and maintained a Buy rating. Analyst Yigal Nochomovitz is re-introducing avasopasem with a 90% probability of success into his revenue model following the recent "stunning" disclosure that Galera discovered an error in their computer code used to compute the statistical significance of the primary endpoint in the ROMAN Phase 3 trial.
- 12/20/2021
|
Check These Penny Stocks Out For Your Watchlist As the Market Dips
- Which penny stocks are you watching as 2021 comes to an end? The post Check These Penny Stocks Out For Your Watchlist As the Market Dips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2021
|
Are Options Traders Betting on a Big Move in Galera (GRTX) Stock?
- Investors need to pay close attention to Galera (GRTX) stock based on the movements in the options market lately.
- 12/15/2021
|
Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch
- Wondering how to trade penny stocks and which could be worth watching? The post Penny Stocks Are Volatile, Here's How to Trade Them and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/14/2021
|
GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today
- Galera Therapeutics (GRTX) stock is rocketing higher on Tuesday after the company revealed corrected results from a Phase 3 clinical trial. The post GRTX Stock Alert: The Surprising News That Has Galera Therapeutics Going Gangbusters Today appeared first on InvestorPlace.
- 12/14/2021
|
Galera Therapeutics Stock (GRTX): Why The Price Surged Today
- The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased by over 118% pre-market today. This is why it happened.
- 12/14/2021
|
Galera to Present at Two Upcoming Investor Conferences in November
- MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.
- 11/15/2021
|
Galera Therapeutics, Inc. (GRTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
- Galera Therapeutics, Inc. (GRTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 11/02/2021
|
Galera Therapeutics plummeted 73% on Tuesday: explore why
- Shares of Galera Therapeutics Inc (NASDAQ: GRTX) tanked 73% on Tuesday after the company said its Avasopasem trial did not meet the primary endpoint. Avasopasem does not ‘significantly' reduce the incidence of SOM Galera was running a Phase III trial for Avasopasem Manganese in patients with locally advanced head and neck cancer (HNC) in hopes […] The post Galera Therapeutics plummeted 73% on Tuesday: explore why appeared first on Invezz.
- 10/19/2021
|
Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
- MALVERN, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Mark J. Bachleda, Pharm.D., M.B.A., as Chief Commercial Officer (CCO) and Jennifer Evans Stacey, Esq., as Chief Legal and Compliance Officer (CLCO) and Secretary. Both executives join Galera with over 25 years of leadership experience within the biopharmaceutical industry.
- 10/12/2021
|
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
- Event to be webcast on Thursday, September 23 at 11:00 a.m. ET
- 09/14/2021
|
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
- Improvements observed in overall survival, progression-free survival, local tumor control, time to metastases, and tumor response rate
- 09/08/2021
|
Galera to Present at Three Upcoming Investor Conferences in September
- MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September.
- 09/07/2021
|
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
- Topline data expected in the second half of 2021
- 06/28/2021
|
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
- Initiation builds on positive overall survival and tumor control data from Phase 1/2 trial
- 05/17/2021
|
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
- MALVERN, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Wednesday, May 12, 2021, at 8:45 a.m. ET.
- 05/05/2021
|
GRTX Stock: From $6.61 To Over $8.80 Pre-Market Explanation
- The stock price of Galera Therapeutics Inc (NASDAQ: GRTX) increased over 34% as it went from a previous close of $6.61 to over $8.80 pre-market. This is why it happened.
- 04/29/2021
|
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
- Near double the median overall survival observed in patients receiving Galera's dismutase mimetic + SBRT versus placebo + SBRT, showing strong therapeutic potential
- 04/28/2021
|
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
- MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021, at 1:50 p.m. ET.
- 03/10/2021
|
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
- MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
- 11/20/2020
|
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
- Presented Promising Interim Data from Placebo-controlled P ilot Dismutase Mimetic SBRT Combination Trial for P ancreatic C ancer
- 11/10/2020
|
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
- MALVERN, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on Tuesday, November 10, 2020, at 11:45 a.m. ET.
- 11/03/2020
|
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
- Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting
- 10/27/2020
|
Galera Therapeutics: Reasonable Valuation With Fast Track And Breakthrough Designation
- Galera Therapeutics is a promising company backed by prestigious venture firms. GC4419's success let to fast track and breakthrough designation by the FDA.
- 09/07/2020
|
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
- Completed Enrollment of Randomized, Blinded, Placebo-controlled Trial of GC4419 in Combination with Radiotherapy in Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H20 Phase 3 ROMAN Trial Remains on Track for Completion of Enrollment in 1H21MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the second quarter ended June 30, 2020, and provided business updates.“During the second quarter, we continued to advance the development of our small molecule superoxide dismutase mimetics in clinical trials evaluating their ability to address radiation toxicities and augment the anti-cancer efficacy of radiation,” said Mel Sorensen, M.D., President and CEO of Galera. “We were pleased to announce the completion of enrollment in our randomized, blinded, placebo-controlled, adaptive Phase 1b/2a trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer (LAPC). We expect to report topline data from that trial as well as initiate a Phase 1b/2a trial of GC4711 with SBRT in non-small cell lung cancer in the second half of this year. We also remain on track to complete enrollment of the Phase 3 ROMAN trial of avasopasem in the first half of next year and to report topline data from the ROMAN trial in the second half of 2021.”Second Quarter 2020 and Recent Corporate Highlights * In July, announced the completion of patient enrollment in the randomized, blinded, placebo-controlled, adaptive Phase 1b/2a clinical trial of avasopasem in combination with SBRT in patients with LAPC. Topline data from this trial are expected in the second half of this year. * In June, dosed the first patient in a Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with head and neck cancer (HNC) undergoing standard-of-care radiotherapy. * Continued enrollment in the Phase 2a clinical trial of avasopasem to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer. * In May, presented new data at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which demonstrated statistically significant reductions by avasopasem on markers of chronic kidney disease due to concurrent cisplatin chemoradiation in a retrospective analysis of the completed Phase 2b trial for the reduction of severe oral mucositis in patients with HNC. As a result, the assessment of these markers has been incorporated into the ROMAN Phase 3 trial. * In May, entered into an amendment to the royalty purchase agreement with Blackstone Life Sciences (Blackstone), which adds $37.5 million in additional funding to the existing $80 million royalty financing commitment that Blackstone (formerly Clarus Ventures) made in 2018. Under the updated agreement terms, Galera agreed to pay Blackstone up to a high single-digit percentage of future commercial royalties from the sales of avasopasem and GC4711 until the total royalty amount achieves an unchanged fixed single-digit multiple of the aggregate financing sum received, upon which the royalty terminates. As partial consideration for the amendment, Galera issued two warrants to Blackstone to purchase an aggregate of 550,661 shares of its common stock at an exercise price of $13.62 per share, each of which will become exercisable upon the receipt by Galera of the applicable specified milestone payment. * In April, announced the appointment of Linda B. West to its Board of Directors. Ms. West most recently served as Vice President for DuPont Corporate Planning & Analyses, where she led the execution of transformational transactions.Second Quarter 2020 Financial Highlights * Research and development expenses were $13.8 million in the second quarter of 2020, compared to $9.5 million for the same period in 2019. The increase was primarily attributable to avasopasem development costs due to increased expenses in the Phase 3 ROMAN trial, additional clinical trials including the Phase 2a trial for the treatment of esophagitis in patients with lung cancer and the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC, and costs associated with manufacturing scale-up activities. Employee-related costs also increased due to increased headcount and share-based compensation expense. * General and administrative expenses were $3.9 million in the second quarter of 2020, compared to $1.8 million for the same period in 2019. The increase was primarily the result of employee-related costs from increased headcount and share-based compensation expense, and increased insurance, professional fees and other operating costs as a result of becoming a public company. * Galera reported a net loss of $(18.7) million, or $(0.75) per share, for the second quarter of 2020, compared to a net loss of $(11.6) million, or $(45.30) per share, for the same period in 2019. * As of June 30, 2020, Galera had cash, cash equivalents and short-term investments of $104.4 million. Galera expects that its existing cash, cash equivalents and short-term investments, together with the expected payments from Blackstone in the amount of $57.5 million upon the achievement of certain clinical enrollment milestones in the ROMAN trial and the anti-cancer program in combination with SBRT under the amended royalty agreement, will enable Galera to fund its operating expenses and capital expenditure requirements into the second half of 2022.About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in a Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer and in a randomized Phase 1/2 trial in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, specifically for use in combination with SBRT, which successfully completed Phase 1 trials in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding expectations surrounding our growth and the continued advancement of our product pipeline, the potential, efficacy, and regulatory and clinical development of Galera’s product candidates, plans and timing for the commencement of and the release of data from Galera’s clinical trials, expected payments from Blackstone, and the sufficiency of Galera’s cash, cash equivalents and short-term investments. These forward-looking statements are based on management’s current expectations.
- 08/10/2020
|
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
- MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2020 BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 9:30 a.m. EDT. A live webcast of the event will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer, its lead indication. It is also being studied in a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer and in a pilot Phase 1/2 trial in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, for SBRT which successfully completed Phase 1 trials in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.Investor Contacts: Christopher Degnan Galera Therapeutics, Inc. 610-725-1500 cdegnan@galeratx.com Jennifer Porcelli Solebury Trout 646-378-2962 jporcelli@soleburytrout.com Media Contact: Gina Cestari 6 Degrees 917-797-7904 gcestari@6degreespr.com
- 07/30/2020
|
Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
- Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- 07/22/2020
|
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
- Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
- 07/15/2020
|
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer
- Topline safety and efficacy data to be reported in the second half of 2020MALVERN, Pa., July 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary small molecule therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC). Galera’s investigational, highly selective small molecule superoxide dismutase (SOD) mimetics are designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen. These dismutase mimetics have potential anti-cancer synergy supported by positive results in multiple preclinical models. The randomized Phase 1b/2a trial is evaluating the safety, progression-free survival and overall response rate of GC4419 in combination with SBRT, compared with SBRT and placebo, in LAPC patients. The trial is also assessing safety and tolerability to determine the recommended dose of SBRT when combined with GC4419 or placebo.“Pancreatic cancer has one of the poorest survival prognoses of common cancers and better treatments are urgently needed. Even when the disease is locally advanced, treatment options have limited impact on this difficult-to-treat cancer,” said Mel Sorensen, M.D., President and CEO of Galera. “This pilot trial is the first to evaluate the anti-cancer effects of our dismutase mimetics in combination of SBRT in patients. We look forward to reporting topline data from this trial in the second half of 2020.”Additional information on the trial can be found on clinicaltrials.gov using the identifier NCT03340974.About GC4419 (Avasopasem Manganese)Galera’s lead product candidate, avasopasem manganese, is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic that is initially being developed for the reduction of radiation-induced severe oral mucositis (SOM) which is not yet approved. Avasopasem is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal tissue from damage associated with radiation therapy. Left untreated, elevated superoxide can damage noncancerous tissues and lead to debilitating side effects, including oral mucositis (OM), which can limit the anti-tumor efficacy of radiation therapy.Avasopasem is currently being studied in the ROMAN trial, a randomized, double blind, placebo-controlled Phase 3 trial of approximately 450 patients (NCT03689712, available at clinicaltrials.gov) to investigate the effects of avasopasem on radiation-induced OM in patients with head and neck cancer. In Galera’s 223-patient, double-blind, randomized, placebo-controlled Phase 2b trial in patients with locally advanced head and neck cancer receiving concurrent radiation therapy, avasopasem produced a statistically significant reduction in duration of severe oral mucositis (SOM) from 19 days to 1.5 days (92 percent) in the 90 mg treatment arm. Avasopasem also demonstrated clinically meaningful reductions in SOM incidence through completion of radiation by 34 percent and in the severity of OM (incidence of Grade 4 OM) by 47 percent in the 90 mg treatment arm. The overall adverse event profile of avasopasem in the Phase 2b trial was similar to that of placebo and consistent with the known adverse effects of chemoradiation, with reductions of blood cell counts, particularly low lymphocyte counts, the most prominent adverse effects. Adverse events considered attributable to avasopasem were limited to mild, transient postural light-headedness or decreased blood pressure. Patients were followed for two years after enrollment and showed no difference in tumor outcomes between active and control, consistent with expectations for combinations with intensity-modulated radiation therapy (IMRT)/cisplatin, suggesting that the efficacy of the chemoradiation therapy was not compromised.Avasopasem is also currently being studied in a Phase 2a trial for its potential to reduce the incidence of radiation-induced esophagitis in patients with lung cancer (NCT04225026, available at clinicaltrials.gov); and a pilot Phase 1/2 trial (NCT03340974, available at clinicaltrials.gov) in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer.The U.S. Food and Drug Administration granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy.About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer, its lead indication. It is also being studied in a Phase 2a trial for its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer and in a pilot Phase 1/2 trial in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, for SBRT which successfully completed Phase 1 trials in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, efficacy, and regulatory and clinical development of Galera’s product candidates, and plans and timing for the release of data from clinical trials. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Galera’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: Galera’s limited operating history; anticipating continued losses for the foreseeable future; needing substantial funding and the ability to raise capital; Galera’s dependence on avasopasem manganese (GC4419); uncertainties inherent in the conduct of clinical trials; difficulties or delays enrolling patients in clinical trials; the FDA’s acceptance of data from clinical trials outside the United States; undesirable side effects from Galera’s product candidates; risks relating to the regulatory approval process; failure to capitalize on more profitable product candidates or indications; ability to receive Breakthrough Therapy Designation or Fast Track Designation for product candidates; failure to obtain regulatory approval of product candidates in the United States or other jurisdictions; ongoing regulatory obligations and continued regulatory review; risks related to commercialization; risks related to competition; ability to retain key employees and manage growth; risks related to intellectual property; inability to maintain collaborations or the failure of these collaborations; Galera’s reliance on third parties; the possibility of system failures or security breaches; liability related to the privacy of health information obtained from clinical trials and product liability lawsuits; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; environmental, health and safety laws and regulations; the impact of the COVID-19 pandemic on Galera’s business and operations, including preclinical studies and clinical trials, and general economic conditions; risks related to ownership of Galera’s common stock; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in Galera’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC), Annual Report on Form 10-K for the year ended December 31, 2019 and Galera’s other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statements speak only as of the date of this press release and are based on information available to Galera as of the date of this release, and Galera assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Contacts: Christopher Degnan Galera Therapeutics, Inc. 610-725-1500 cdegnan@galeratx.comJennifer Porcelli Solebury Trout 646-378-2962 jporcelli@soleburytrout.comMedia Contact: Gina Cestari 6 Degrees 917-797-7904 gcestari@6degreespr.com
- 07/13/2020
|
Hedge Funds Are Selling Galera Therapeutics, Inc. (GRTX)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 06/10/2020
|
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced new data from a retrospective analysis of pre- and post-treatment markers of kidney function of patients treated with lead candidate avasopasem manganese in its Phase 2b trial for the reduction of chemoradiation-induced severe oral mucositis (SOM). The data are featured in an American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program poster presentation now available for on-demand viewing in ASCO’s virtual program.
- 05/29/2020
|
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
- 05/18/2020
|
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a retrospective analysis of Phase 2b trial data demonstrating the potential renal protective activity of lead candidate avasopasem manganese (GC4419), and two ongoing clinical trials evaluating avasopasem, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place May 29-31, 2020. “We look forward to sharing important clinical updates that underscore the potential of avasopasem to address radiation-induced toxicities and enhance the anti-cancer efficacy of chemoradiotherapy,” said Mel Sorensen, M.D., President and CEO of Galera.
- 05/13/2020
|
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2020, and provided business updates. “Despite these unprecedented times, we have continued to progress patient enrollment in our three ongoing clinical trials of lead candidate avasopasem manganese (GC4419),” said Mel Sorensen, M.D., President and CEO of Galera. As a result, we are increasing the size of the Phase 3 ROMAN trial for the treatment of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer to ensure we are positioned to achieve our targeted number of patients for the NDA safety database, and are updating our guidance for completing enrollment to the first half of 2021 and for reporting topline data to the second half of 2021.
- 05/12/2020
|
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
- MALVERN, Pa., May 05, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
- 05/05/2020
|
Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program
- MALVERN, Penn., April 30, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
- 04/30/2020
|
Galera Therapeutics (NASDAQ:GRTX) Upgraded at Zacks Investment Research
- Galera Therapeutics (NASDAQ:GRTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $14.00 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential downside of 2.85% from the […]
- 04/30/2020
|
Galera Therapeutics (NASDAQ:GRTX) Stock Rating Lowered by Zacks Investment Research
- Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, “Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company’s […]
- 04/23/2020
|
Galera Therapeutics (NASDAQ:GRTX) Stock Rating Upgraded by Zacks Investment Research
- Galera Therapeutics (NASDAQ:GRTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $14.00 price target on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 13.09% from the company’s previous close. […]
- 04/22/2020
|
Galera Therapeutics (NASDAQ:GRTX) Raised to "Buy" at Zacks Investment Research
- Zacks Investment Research upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has $12.00 target price on the stock. According to Zacks, “Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and […]
- 04/18/2020
|
Galera Therapeutics (NASDAQ:GRTX) Rating Lowered to Hold at Zacks Investment Research
- Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company’s product candidate […]
- 04/17/2020
|
Galera Therapeutics Appoints Linda B. West to Board of Directors
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the appointment of Linda B. West to its board of directors. Additionally, as part of a planned transition, Jason Fuller, Ph.D., will not stand for re-election at Galera’s annual meeting. “Linda is a proven and highly regarded business leader with extensive experience in transforming business operations, as well as spearheading governance, compliance and regulatory activities,” said Mel Sorensen, M.D., President and CEO of Galera.
- 04/02/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
- - Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer.
- 03/10/2020
|
Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced full tumor outcomes results from the two-year follow-up of patients with head and neck cancer treated with avasopasem manganese (GC4419), Galera’s lead product candidate for severe oral mucositis (SOM), in a Phase 2b clinical trial. The results will be presented February 28, 2020, during a late-breaking oral presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, Ariz.
- 02/27/2020
|
Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium
- MALVERN, Pa., Feb. 24, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
- 02/24/2020
|
Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
- MALVERN, Pa., Feb. 19, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
- 02/19/2020
|
Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the first patient has been dosed in a Phase 2a clinical trial of lead product candidate avasopasem manganese (GC4419) to evaluate its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer. The open-label, multi-center trial will evaluate the efficacy of avasopasem manganese, a highly selective small molecule superoxide dismutase (SOD) mimetic, in reducing the incidence of severe (Grade 2 or worse on the NCI Common Terminology Criteria for Adverse Events scale) acute radiation-induced esophagitis in patients with lung cancer receiving chemoradiotherapy.
- 01/07/2020
|
3 “Strong Buy” Healthcare Stocks That Can Double in 2020
- Unphased by some risk? If the answer is yes, then healthcare stocks might be the way to go. These names tend to be more volatile in nature as a single catalyst like trial data or a verdict from the FDA can either propel shares upward or send them plummeting overnight.While the degree of risk involved can turn-off some potential investors, others are enticed by the possibility of sky-high rewards. Take Agile Therapeutics, for example. Shares popped over 200% after an FDA AdCom voted in favor of Twirla, its contraceptive patch.That being said, when it comes to biotechs it’s important to do your due diligence as not all names in the space are ready for takeoff. To narrow down only the most compelling stocks, we took advantage of TipRanks’ Stock Screener. The tool pointed us in the direction of 3 biotech stocks with huge upside potential from the current share price. We’re talking 100% or more here. If that wasn’t enough, we found out that the Street is also in favor of these names as each has earned a “Strong Buy” consensus rating.Cellectis SA (CLLS)Who’d have thought that editing our genes to treat cancer would become a possibility? Cellectis had just that thought. The biotech uses its innovative TALEN technology to edit the Chimeric Antigen Receptor (CAR) T-cells taken from healthy donors to create “off-the-shelf” immunotherapy product candidates that could work for the largest amount of people. Even though shares have dipped year-to-date, some members of the Street see major growth in store.While the company did report a net loss in its third quarter, Wells Fargo analyst Jim Birchenough reminds investors to consider the progress of its CAR T-cell platform and pipeline. CLLS has three wholly owned clinical UCART candidates, with it recently administering CS1 CAR-T, UCARTCS1, in the first multiple myeloma patient in the MELANI-01 trial. In addition, the trials for the two other products are open for enrollment.All of this has impressed Birchenough, noting that the UCART pipeline is even more promising thanks to manufacturing changes. “Since the original UCART123 IND filing, CLLS has improved the reliability and reproducibility of the UCART manufacturing process and, for UCART123 these changes necessitated filing a new IND. While CLLS can supply several hundred patients from a single healthy donor, the company has manufactured several batches of each of its UCART products from several donors using the refined manufacturing process that accommodates inherent variability between donors,” he explained.As a result, the five-star analyst left the Outperform rating and $47 price target as is. Given this target, the analyst thinks that shares could soar 195% in the next twelve months. (To watch Birchenough’s track record, click here)Like Birchenough, Ladenburg Thalmann’s Wangzhi Li points to the UCART products as the key component of his bullish thesis. “We are encouraged that UCART-CS1 now dosed 1st pts, and UCART123 and UCART22 expect to dose pts in the near term. We see clinical data reports from any of the programs (likely in 2020) as key catalysts for CLLS story, and a clinical win could be a key to potentially unlock CLLS value,” the four-star analyst noted. To this end, Li reiterated the bullish call and $40 price target. (To watch Li’s track record, click here)Turning now to Wall Street, other analysts are on the same page. With 4 Buys and 1 Hold received in the last three months, the word on the Street is that CLLS is a Strong Buy. On top of this, the $42.75 average price target brings the potential twelve-month gain to 173%. (See Cellectis stock analysis on TipRanks)Personalis (PSNL)Also focusing on treatments for cancer, Personalis provides more comprehensive molecular data about each patient’s tumor. Since its June IPO, shares have definitely struggled, but the tide could be turning according to analysts.Kevin DeGeeter of Oppenheimer tells investors that he is especially excited about PSNL’s collaboration with Merck KGaA, arguing that it validates the ImmunoID Next platform’s immunophenotyping capacity in a research setting. Adding to the good news, the analyst cites the expansion of the number of ordering customers, specifically larger customers with multiple potential research projects, as driving possible customer base growth in the first half of 2020.This prompted the analyst to comment, “We view PSNL as a proxy for continued growth in pharmaceutical immune oncology research budgets and differentiated based on its complete focus on corporate and government customers (no clinical testing). We view this focus as a key asset supporting a premium product offering emphasizing quality of sequencing result and flexible menu.” Bearing this in mind, DeGeeter gave PSNL his stamp of approval, maintaining the Outperform rating and $26 price target. As such, the upside potential comes in at a whopping 155%. (To watch DeGeeter’s track record, click here)Meanwhile, Cowen’s Doug Schenkel did acknowledge that the VA-heavy mix poses a cause for concern. However, he thinks that the valuation still reflects a compelling opportunity, lending itself to his conclusion that the biotech is a good Buy. (To watch Schenkel’s track record, click here)What does the rest of the Street have to say? Looking at the 100% Street support, the consensus is unanimous: PSNL is a Strong Buy. While the $21 average price target is lower than DeGeeter’s estimate, it still suggests that shares could more than double in the twelve months ahead. (See Personalis stock analysis on TipRanks)Galera Therapeutics (GRTX)Making its market debut this past November, Galera Therapeutics is working on developing mechanism-based therapies for cancer patients. Given the huge unmet need that could be met by the biotech’s products, one analyst has high hopes.BTIG analyst Robert Hazlett highlights GRTX’s candidates that have the potential to not only protect patients from radiotherapy induced toxicities but also to enhance the efficacy of the radiotherapy itself as a key point of strength. Its lead asset, GC4419, is an IV superoxide dismutase (SOD) mimetic, currently progressing through a Phase 3 trial for use in the reduction of severe oral mucositis (SOM) in head and neck cancer patients who are undergoing radiotherapy.In Phase 2b, data indicated that the drug was able to cut the duration and incidence of SOM, leading to an FDA Breakthrough Designation for GC4419. As SOM occurs in about 70% of patients receiving radiation for head and neck cancer, Hazlett sees a substantial material opportunity. “With nothing currently approved for SOM in head & neck cancer patients, we estimate GC4419’s peak revenue potential in this setting in the US is greater than $500 million,” he stated.It also doesn’t hurt that GRTX is evaluating GC4419’s ability to reduce esophagitis brought on by radiotherapy in patients with lung cancer. As enrollment could begin in the first half of 2020, Hazlett puts the peak potential in the U.S. at over $300 million.Based on this potential, it’s no wonder, then, that the five-star analyst initiated coverage with a Buy recommendation. At the $30 price target, shares could skyrocket 205% in the coming twelve months. (To watch Hazlett’s track record, click here)All in all, the rest of the Street also likes what it’s seeing. 3 Buys and 1 Hold assigned in the last three months amount to a Strong Buy consensus. Thanks to the $19.75 average price target, the upside potential lands at nearly 100%. (See Galera stock analysis on TipRanks)
- 12/17/2019
|
Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
- - Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds - - Progressed Pivotal Clinical Trial of GC4419 in Head & Neck.
- 12/10/2019
|
Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology
- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that full results from the 223-patient, randomized, double-blind Phase 2b clinical trial of lead candidate GC4419 (avasopasem manganese) in patients with locally advanced head and neck cancer have been published in the Journal of Clinical Oncology, a journal of the American Society of Clinical Oncology (ASCO).
- 12/05/2019
|
Analysts: Galera Has Novel Pipeline For Radiation Oncology Market, Commercialization Remains Headwind
- Galera Therapeutics Inc (NASDAQ: GRTX ), a biopharma company working on novel therapeutics for transforming radiotherapy treatment in cancer, recently IPO'd, offering 5 million shares at $12 apiece. Following ...
- 12/02/2019
|
Galera Therapeutics Announces Pricing of Initial Public Offering
- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $12.00 per share, for total gross proceeds of $60.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galera. All of the common stock is being offered by Galera.
- 11/07/2019
|
